Becaplermin

Last updated

Becaplermin
Clinical data
Trade names Regranex
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a699049
Routes of
administration 		Topical
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
ChEMBL
CompTox Dashboard (EPA)
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Becaplermin, sold under the brand name Regranex, is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. [1] It is also known as "platelet-derived growth factor BB". [1]

Contents

Medical uses

Becaplermin is used for the treatment of diabetic foot ulcers. [2] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster. [3] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care. [4]

The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. [1] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [5]

Contraindications

Becaplermin must not be used at the site of a skin cancer. [6]

Adverse effects

The most common side effects in clinical studies were erythematous rashes. [6]

References

  1. 1 2 3 4 "Regranex- becaplermin gel". DailyMed. 11 December 2023. Retrieved 26 October 2024.
  2. ↑ Nagai MK, Embil JM (February 2002). "Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers". Expert Opinion on Biological Therapy. 2 (2): 211–8. doi:10.1517/14712598.2.2.211. PMID   11849120. S2CID   28408255.
  3. ↑ Wieman TJ, Smiell JM, Su Y (May 1998). "Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study". Diabetes Care. 21 (5): 822–7. doi:10.2337/diacare.21.5.822. PMID   9589248. S2CID   20595962.
  4. ↑ Persson U, Willis M, Odegaard K, Apelqvist J (2000). "The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data". Value in Health. 3 (Suppl 1): 39–46. doi: 10.1046/j.1524-4733.2000.36027.x . PMID   16464208.
  5. ↑ Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
  6. 1 2 FDA Professional Drug Information for Regranex.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.